Teva Pharmaceutical Industries reported a robust second quarter for 2026, characterized by significant growth in its innovative portfolio and a successful shift in its core financial strategy. During the earnings call held on Wednesday, July 29, 2026, at 8:00 a.m. ET, the company highlighted how high-performing brands—AUSTEDO, AJOVY, and UZEDY—are successfully offsetting headwinds from generic REVLIMID losses and positioning the firm for long-term value creation.
Driving Growth Through Innovation
CEO Richard Francis emphasized that the “Pivot to Growth” strategy, launched in 2023, is delivering tangible results. The innovative portfolio grew by 43% year-over-year, with AUSTEDO up 40%, UZEDY up 43%, and AJOVY up 56%. Consequently, Teva has raised its full-year revenue guidance for these key assets.
AUSTEDO remains a primary growth driver, with U.S. revenue reaching $676 million. The company is confident in its path to exceeding $3 billion in peak sales. Meanwhile, UZEDY has established itself as a leader in long-acting injectables for schizophrenia, capturing significant market share. Building on this momentum, Teva is preparing for the Q4 launch of its olanzapine long-acting injectable, targeting a massive unmet need in the schizophrenia treatment market.
Pipeline Expansion and Clinical Milestones
The company’s R&D division, led by Dr. Eric Hughes, is executing on eight major pipeline milestones this year. A key development is the inclusion of ecopipane for Tourette syndrome, which is currently under FDA review with a potential launch in the first half of 2027.
Furthermore, Teva announced two new indications for its pipeline asset duvaqitub: hidradenitis suppurativa and fibrosthenotic Crohn’s disease. These additions are expected to significantly broaden the drug’s therapeutic impact. Dr. Hughes also shared promising proof-of-concept data for the anti-IL-15 program in vitiligo, noting that 75% of patients reported improvements in facial appearance after just two doses.
Financial Transformation and Market Positioning
CFO Eli Kalif highlighted that Teva’s financial profile is fundamentally changing. Despite the impact of generic REVLIMID, the company’s underlying business remains stable. Notable financial achievements include:
- An 80-basis-point increase in non-GAAP gross margins.
- A 31% increase in free cash flow.
- An upgrade to investment grade by Fitch, validating the company’s disciplined capital allocation.
The company’s commitment to its “Pivot to Growth” strategy is further evidenced by its focus on biosimilars, where it now has 15 products on the market and 14 in the pipeline. With a target of exceeding $800 million in biosimilar revenue by 2027, Teva is solidifying its role as a key player in the biopharma space.
Looking Ahead: Strategic Focus
Teva is moving toward a direct ordinary share listing on the New York Stock Exchange, expected in September, to enhance accessibility for a broader range of investors. As the company continues to execute its strategy, it remains focused on reaching its 30% operating margin target by 2027, driven by a portfolio increasingly weighted toward high-value innovation.
Deixe um comentário